secwatch.observer — SEC 8-K summary
======================================

Issuer:     Rein Therapeutics, Inc. (RNTX)
CIK:        0001420565
Form:       8-K
Filed at:   2024-04-15T23:59:59+00:00
Accession:  0001193125-24-096389
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aileron reports Q4 net loss $7.3M; expects LTI-03 topline results in Q3 2024
----------------------------------------------------------------------------

- Net loss Q4 2023 $7.3M ($1.54 per share) vs $4.5M ($1.00) in Q4 2022; FY 2023 net loss $3.42 per share vs $6.02.
- Cash, cash equivalents and investments $17.3M at Dec 31, 2023; runway into Q4 2024.
- Completed merger with Lung Therapeutics in Oct 2023; raised ~$18M in private placement.
- Appointed Brian Windsor as President and CEO in March 2024 (ex-CEO of Lung).
- LTI-03 Phase 1b topline results in IPF expected Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/0001193125-24-096389-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420565/000119312524096389/d817402d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-096389

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer